CN104546880A - External preparation for treating facial seborrheic dermatitis - Google Patents
External preparation for treating facial seborrheic dermatitis Download PDFInfo
- Publication number
- CN104546880A CN104546880A CN201510006320.2A CN201510006320A CN104546880A CN 104546880 A CN104546880 A CN 104546880A CN 201510006320 A CN201510006320 A CN 201510006320A CN 104546880 A CN104546880 A CN 104546880A
- Authority
- CN
- China
- Prior art keywords
- glycerol
- seborrheic dermatitis
- external preparation
- ketoconazole
- ceramide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000008742 seborrheic dermatitis Diseases 0.000 title claims abstract description 36
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 31
- 230000001815 facial effect Effects 0.000 title claims abstract description 19
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 91
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims abstract description 23
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims abstract description 23
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims abstract description 23
- 229940106189 ceramide Drugs 0.000 claims abstract description 23
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims abstract description 23
- 229960004125 ketoconazole Drugs 0.000 claims abstract description 23
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims abstract description 23
- MCSINKKTEDDPNK-UHFFFAOYSA-N propyl propionate Chemical compound CCCOC(=O)CC MCSINKKTEDDPNK-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229960002152 chlorhexidine acetate Drugs 0.000 claims abstract description 17
- 238000003756 stirring Methods 0.000 claims description 27
- 229930182470 glycoside Natural products 0.000 claims description 21
- 150000002338 glycosides Chemical class 0.000 claims description 21
- 239000008346 aqueous phase Substances 0.000 claims description 20
- 239000012071 phase Substances 0.000 claims description 20
- 239000000758 substrate Substances 0.000 claims description 19
- 239000004615 ingredient Substances 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 claims description 8
- 235000021355 Stearic acid Nutrition 0.000 claims description 8
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 8
- 239000012153 distilled water Substances 0.000 claims description 8
- 239000012467 final product Substances 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 8
- 229940057995 liquid paraffin Drugs 0.000 claims description 8
- 239000011159 matrix material Substances 0.000 claims description 8
- 238000002844 melting Methods 0.000 claims description 8
- 230000008018 melting Effects 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 8
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 8
- 239000008117 stearic acid Substances 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 5
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 claims description 4
- 229960005150 glycerol Drugs 0.000 claims description 4
- 229940099259 vaseline Drugs 0.000 claims description 4
- 241000191963 Staphylococcus epidermidis Species 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 5
- 230000003020 moisturizing effect Effects 0.000 abstract description 4
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 230000004054 inflammatory process Effects 0.000 abstract description 3
- 241000555688 Malassezia furfur Species 0.000 abstract description 2
- 230000037365 barrier function of the epidermis Effects 0.000 abstract description 2
- 239000004378 Glycyrrhizin Substances 0.000 abstract 2
- 235000011187 glycerol Nutrition 0.000 abstract 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 abstract 2
- 229960004949 glycyrrhizic acid Drugs 0.000 abstract 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 abstract 2
- 235000019410 glycyrrhizin Nutrition 0.000 abstract 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract 2
- 208000003251 Pruritus Diseases 0.000 description 13
- 239000000839 emulsion Substances 0.000 description 6
- 206010015150 Erythema Diseases 0.000 description 5
- 206010000496 acne Diseases 0.000 description 5
- 231100000321 erythema Toxicity 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 239000000080 wetting agent Substances 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 2
- 238000003287 bathing Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000010422 painting Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 231100000255 pathogenic effect Toxicity 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000101040 Pityriasis Species 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940046731 calcineurin inhibitors Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an external preparation for treating facial seborrheic dermatitis, belongs to the technical field of medical, dental or dressing preparations, and in particular relates to an external preparation for treating facial seborrheic dermatitis. The external preparation disclosed by the invention at least comprises the following medicinal components: 0.05-0.1 part of chlorhexidine acetate, 0.05-0.15 part of ketoconazole, 0.05-0.15 part of ceramide, 8-12 parts of glycerin and 0.8-1.2 parts of glycyrrhizin. According to the external preparation disclosed by the invention, the staphylococcus epidermidis can be effectively killed by chlorhexidine acetate, the pityrosporum orbiculare is effectively inhibited by ketoconazole, the inflammatory reaction is inhibited by the glycyrrhizin, the natural moisturizing factors of cuticle are increased by the glycerin, and the epidermal barrier function is repaired by the ceramide. According to the comprehensive effects of the five medical components, the facial seborrheic dermatitis can be effectively treated.
Description
Technical field
The invention belongs to the preparation technical field of medical, dental or dressing, specifically, relate to a kind of external preparation for the treatment of facial seborrheic dermatitis.
Background technology
Seborrheic dermatitis (Seborrheic Dermatitis, SD) be occur in the chronic papulosquamous of one at seborrhea position, shallow table inflammatory dermatoses, the pityriasis rubra pimple of typical rash merges the kermesinus, the yellowish red color speckle that are formed, on cover greasy scales or crust, can with pruritus in various degree.The cause of disease is not quite clear, think relevant with pityrosporum furfur field planting activity in the past, but antifungal therapy effect is not given prominence to, and its effectiveness exists academic dispute.Current facial seborrheic dermatitis Therapeutic Method comprises simple anti-inflammatory drug (as hormones external preparation, calcineurin inhibitors), assists with skin moisture-keeping skin care item, and effective percentage is lower; And symptom easily recurs after drug withdrawal.
Summary of the invention
The present invention is exactly for the above-mentioned problems in the prior art, provides a kind of therapeutic effect good and the external preparation of the treatment of not easily recurring face seborrheic dermatitis.
Research through us finds: 1) field planting of facial patients with seborrheic dermatitis staphylococcus epidermidis is increased, and (average is nearly 90cfu/cm respectively to have the significant difference of highly significant than normal population
2and 12cfu/cm
2), externally used antimicrobial treatment effectively can improve patients symptomatic's (disease severity integral mean is down to 0.3 by about 0.9), sees accompanying drawing 1, points out the staphylococcus epidermidis of high field planting to have pathogenic effects; 2) experiment in vitro finds that Malassezia furfur thalline or culture supernatant can promote that staphylococcus epidermidis is bred, and point out these two kinds of mushrooms to have collaborative pathogenic effects, and the effect of staphylococcus epidermidis may be more direct; 3) the skin barrier protective capability of seborrheic dermatitis declines, and shows as transdermal water and loses increase.The transdermal water of patients with seborrheic dermatitis cutaneous lesion loses average more than 37g/hm
2, and normal control population's average is 23g/hm
2, have significant significant difference.The destruction of this barrier is one of key factor of secondary bacterial height field planting.Based on above discovery, the present invention adopts following technical scheme, formulates a kind of externally used compound preparation of the novel facial seborrheic dermatitis of effective treatment, comprehensively gives therapeutic intervention for the pathogenesis etiology of this disease and mechanism from several angle, under the prerequisite ensureing safety, improve the effective percentage for the treatment of.
External preparation of the present invention at least comprises following ingredient: chlorhexidine acetate 0.05-0.1 part, ketoconazole 0.05-0.15 part, ceramide 0.05-0.15 part, glycerol 8-12 part, glycyrrhizic glycoside 0.8-1.2 part.
Various raw material role in formula is as follows.
Chlorhexidine acetate: effectively kill staphylococcus epidermidis.
Ketoconazole: effectively suppress pityrosporum furfur.
Ceramide: efficient moisture-retention agent, is fairly absorbed by the skin, and can promote that other nutrient substance permeates, make skin keep elasticity, smooth careful; Especially remarkable to geroderma moisturizing effectiveness.
Glycerol: increase the cuticular nature moisturizing factor of skin of face.
Glycyrrhizic glycoside: can inflammation-inhibiting reaction.
The present invention treats the preparation method of the oil-in-water dosage form of facial seborrheic dermatitis external preparation: glycerol and triethanolamine are added in the distilled water boiled, stirring and dissolving, and temperature is also remained on 80-85 DEG C, as aqueous phase by cooling; By stearic acid, Oleum Ricini and liquid paraffin heating and melting, temperature remains on 80-85 DEG C, as oil phase; By aforementioned oil phase under slow stirring, add in aforementioned aqueous phase, complete matrix composition; When substrate is cooled to 50-60 DEG C, ingredient acid hibitane, ketoconazole, ceramide, glycerol, glycyrrhizic glycoside are together added in aforementioned substrate, stirs according to same direction, be cooled to room temperature and get final product.
The present invention treats the preparation method of the Water-In-Oil dosage form of facial seborrheic dermatitis external preparation: glycerol and triethanolamine are added in the distilled water boiled, stirring and dissolving, and temperature is also remained on 80-85 DEG C, as aqueous phase by cooling; By stearic acid, Oleum Ricini and liquid paraffin heating and melting, temperature remains on 80-85 DEG C, as oil phase; By aforementioned aqueous phase under slow stirring, add in aforementioned oil phase, complete matrix composition; When substrate is cooled to 50-60 DEG C, ingredient acid hibitane, ketoconazole, ceramide, glycerol, glycyrrhizic glycoside are together added in aforementioned substrate, stirs according to same direction, be cooled to room temperature and get final product.
The present invention treats the preparation method of the ointment dosage form of facial seborrheic dermatitis external preparation: take vaseline as substrate (addition is 8-12 weight portion), add ingredient chlorhexidine acetate 0.05-0.1 part, ketoconazole 0.05-0.15 part, ceramide 0.05-0.15 part, glycerol 8-12 part, glycyrrhizic glycoside 0.8-1.2 part, stir and get final product.
Make the oil phase of Emulsion: oil phase is the main constituent of Emulsion, and ingredient is dispersed in aqueous phase or oil phase according to the physical property of self.
Make the aqueous phase of Emulsion: aqueous phase is the main constituent of Emulsion, and ingredient is dispersed in aqueous phase or oil phase according to the physical property of self.
Make the emulsifying agent of Emulsion: emulsifying agent (being vaseline in the present invention) has significant surface activity; Interfacial film can be formed around drop; Electric screen barrier can be formed on drop surface; Dielectric viscosity can be increased; And to have good to acid, alkali, salt stable, nonirritant.
Compared with prior art beneficial effect of the present invention: external preparation of the present invention can effectively be killed staphylococcus epidermidis, ketoconazole by chlorhexidine acetate and effectively suppress that pityrosporum furfur, glycyrrhizic glycoside inflammation-inhibiting react, glycerol increases cuticular nature moisturizing factor, and ceramide repairs epidermal barrier function.By the comprehensive function of above-mentioned five kinds of ingredients, the effectively facial seborrheic dermatitis for the treatment of; In clinical experiment, patients receiving treatment is totally 75 examples, and wherein 26 examples are effective, and effectively, total effective rate reaches 94.7% to 45 examples.Utilize this Emulsion obtained by five kinds of medicines and ointment painting convenient, make expense of raw materials relative moderate.
Accompanying drawing explanation
Fig. 1 is that the embodiment of the present invention 1 and embodiment 2 treat Comparison of therapeutic figure before and after seborrheic dermatitis with existing wetting agent.# p value <0.05, the improvement degree of embodiment two treatment group is better than wetting agent treatment group.* p value <0.05, the improvement degree of embodiment one treatment group is better than wetting agent treatment group.Wherein, wetting agent is that (GlaxoSmithKline PLC Investment Co., Ltd produces the good emollient cream of Shi Taifu mist silk, and during use, in the front and back of cutaneous lesion external foregoing pharmaceutical, 2 hours planted agents avoid using the outer painting in the whole body once a day, 0.5g/ palm area.As bathing on the same day, then complete in 5 minutes after bathing, during the more moistening state of skin).
Detailed description of the invention
Embodiment 1: 6.2g glycerol and 10g triethanolamine are added in the 55ml distilled water boiled, stirring and dissolving, temperature is also remained on 80-85 DEG C, as aqueous phase by cooling; By 12.4g stearic acid, 12.4g Oleum Ricini and 12.4g liquid paraffin heating and melting, temperature remains on 80-85 DEG C, as oil phase; By aforementioned oil phase under slow stirring, add in aforementioned aqueous phase, complete matrix composition; When substrate is cooled to 50-60 DEG C, ingredient 0.05g chlorhexidine acetate, 0.05g ketoconazole, 0.05g ceramide, 8g glycerol, 0.8g glycyrrhizic glycoside are together added in aforementioned substrate, stirs according to same direction, be cooled to room temperature and get final product.
Embodiment 2: 6.2g glycerol and 10g triethanolamine are added in the 55ml distilled water boiled, stirring and dissolving, temperature is also remained on 80-85 DEG C, as aqueous phase by cooling; By 12.4g stearic acid, 12.4g Oleum Ricini and 12.4g liquid paraffin heating and melting, temperature remains on 80-85 DEG C, as oil phase; By aforementioned aqueous phase under slow stirring, add in aforementioned oil phase, complete matrix composition; When substrate is cooled to 50-60 DEG C, ingredient 0.08g chlorhexidine acetate, 0.1g ketoconazole, 0.1g ceramide, 10g glycerol, 1g glycyrrhizic glycoside are together added in aforementioned substrate, stirs according to same direction, be cooled to room temperature and get final product.
Embodiment 3: be that substrate chooses 10g with vaseline, add ingredient 0.1g chlorhexidine acetate, 0.15g ketoconazole, 0.15g ceramide, 12g glycerol, 1.2g glycyrrhizic glycoside, stir and get final product.
Embodiment 4: chlorhexidine acetate 0.1 part, ketoconazole 0.15 part, ceramide 0.1 part, glycerol 10 parts, glycyrrhizic glycoside 1.2 parts.
Embodiment 5: chlorhexidine acetate 0.0 part, ketoconazole 0.1 part, ceramide 0.15 part, glycerol 8 parts, glycyrrhizic glycoside 1 part.
Embodiment 6: chlorhexidine acetate part 0.08 part, ketoconazole 0.05 part, ceramide 0.05 part, glycerol 12 parts, glycyrrhizic glycoside 0.8 part.
Case 1: Lee, female 45 years old; Seborrheic dermatitis medical history half a year, be dispersed in the erythema of distribution in nasolabial fold, lower jaw part as seen, above cover greasy scales, pruritus is obvious.Right figure is the photo of application antibiotics medicinal ointment therapy after two weeks, and visible erythema, squama obviously reduce, and pruritus is alleviated, and treatment effectively.Seborrheic dermatitis area severity index SDSIA is down to 0.1 by 0.3, and pruritus index is down to 0 by 3.
Case 2: Zhao, man 56 years old; Seborrheic dermatitis medical history three months, be dispersed in the pimple of distribution as seen in two sided buccal, forehead, face goes out Chuck Steak, conscious pruritus.Right figure is the photo of antibiotics medicinal ointment therapy after two weeks.Visible pimple obviously reduces, and pruritus alleviates, and treatment effectively.Seborrheic dermatitis area severity index SDSIA is down to 0.1 by 0.6, and pruritus index is down to 0 by 3.
Case 3: Zhang, man 72 years old; Patient is HIV elderly men, HIV medical history 2 years, seborrheic dermatitis medical history 1 year.Repeatedly in Face and cheek, nasolabial fold, lower jaw part generation erythema, pimple in 1 year, conscious pruritus.Right figure is the photo of antibiotics medicinal ointment therapy after 2 weeks, and visible erythema, pimple disappear, and pruritus is alleviated, and treatment effectively.Seborrheic dermatitis area severity index SDSIA is down to 0.1 by 0.3, and pruritus index is down to 0 by 3.
Note: SDASI marking system (seborrheic dermatitis area severity index) and pruritus scoring: the classification of severity of erythema, squama: 0=is without skin lesion, and 1=is slight, 2=moderate, 3=severe.The multiplication coefficient of the different boundaries region of anatomy is as follows: frons 0.1, scalp portion 0.4, nasolabial fold 0.1, eyebrow 0.1, after ear 0.1, and ear 0.1, lower jaw part 0.1, two colpus 0.2, back 0.2.The score addition of different parts and SDASI mark (0-12.6).Pruritus grading: 0=without pruritus, 2=moderate that 1=is slight, 3=severe.
Claims (9)
1. treat an external preparation for facial seborrheic dermatitis, it is characterized in that: at least comprise following ingredient: chlorhexidine acetate 0.05-0.1 part, ketoconazole 0.05-0.15 part, ceramide 0.05-0.15 part, glycerol 8-12 part, glycyrrhizic glycoside 0.8-1.2 part.
2. the external preparation of the facial seborrheic dermatitis for the treatment of as claimed in claim 1, is characterized in that: chlorhexidine acetate 0.1 part, ketoconazole 0.15 part, ceramide 0.1 part, glycerol 10 parts, glycyrrhizic glycoside 1.2 parts.
3. the external preparation of the facial seborrheic dermatitis for the treatment of as claimed in claim 2, is characterized in that: chlorhexidine acetate 0.0 part, ketoconazole 0.1 part, ceramide 0.15 part, glycerol 8 parts, glycyrrhizic glycoside 1 part.
4. the external preparation of the facial seborrheic dermatitis for the treatment of as claimed in claim 3, is characterized in that: chlorhexidine acetate part 0.08 part, ketoconazole 0.05 part, ceramide 0.05 part, glycerol 12 parts, glycyrrhizic glycoside 8 parts.
5. the preparation method of the external preparation of the treatment face seborrheic dermatitis as described in claim 1-4, it is characterized in that: glycerol and triethanolamine are added in the distilled water boiled, stirring and dissolving, temperature is also remained on 80-85, as aqueous phase by cooling; By stearic acid, Oleum Ricini and liquid paraffin heating and melting, temperature remains on 80-85 DEG C, as oil phase; By aforementioned aqueous phase under slow stirring, add in aforementioned oil phase, complete matrix composition; When substrate is cooled to 50-60 DEG C, ingredient acid hibitane, ketoconazole, ceramide, glycerol, glycyrrhizic glycoside are together added in aforementioned substrate, stirs according to same direction, be cooled to room temperature and namely obtain the present invention.
6. the preparation method of the external preparation of the treatment face seborrheic dermatitis as described in claim 1-4, it is characterized in that: glycerol and triethanolamine are added in the distilled water boiled, stirring and dissolving, temperature is also remained on 80-85 DEG C, as aqueous phase by cooling; By stearic acid, Oleum Ricini and liquid paraffin heating and melting, temperature remains on 80-85 DEG C, as oil phase; By aforementioned oil phase under slow stirring, add in aforementioned aqueous phase, complete matrix composition; When substrate is cooled to 50-60 DEG C, ingredient acid hibitane, ketoconazole, ceramide, glycerol, glycyrrhizic glycoside are together added in aforementioned substrate, stirs according to same direction, be cooled to room temperature and namely obtain the present invention.
7. the external preparation of the treatment face seborrheic dermatitis as described in claim 1-4, it is characterized in that: take vaseline as substrate (addition is 8-12 weight portion), add ingredient chlorhexidine acetate 0.05-0.1 part, ketoconazole 0.05-0.15 part, ceramide 0.05-0.15 part, glycerol 8-12 part, glycyrrhizic glycoside 0.8-1.2 part, stir and obtain the present invention.
8. the external preparation of the facial seborrheic dermatitis for the treatment of as claimed in claim 6, is characterized in that: 6.2g glycerol and 10g triethanolamine are added in the 55ml distilled water boiled, stirring and dissolving, and temperature is also remained on 80-85 DEG C, as aqueous phase by cooling; By 12.4g stearic acid, 12.4g Oleum Ricini and 12.4g liquid paraffin heating and melting, temperature remains on 80-85 DEG C, as oil phase; By aforementioned oil phase under slow stirring, add in aforementioned aqueous phase, complete matrix composition; When substrate is cooled to 50-60 DEG C, ingredient 0.05g chlorhexidine acetate, 0.05g ketoconazole, 0.05g ceramide, 8g glycerol, 0.8g glycyrrhizic glycoside are together added in aforementioned substrate, stirs according to same direction, be cooled to room temperature and get final product.
9. the external preparation of the facial seborrheic dermatitis for the treatment of as claimed in claim 6, is characterized in that: 6.2g glycerol and 10g triethanolamine are added in the 55ml distilled water boiled, stirring and dissolving, and temperature is also remained on 80-85 DEG C, as aqueous phase by cooling; By 12.4g stearic acid, 12.4g Oleum Ricini and 12.4g liquid paraffin heating and melting, temperature remains on 80-85 DEG C, as oil phase; By aforementioned aqueous phase under slow stirring, add in aforementioned oil phase, complete matrix composition; When substrate is cooled to 50-60 DEG C, ingredient 0.08g chlorhexidine acetate, 0.1g ketoconazole, 0.1g ceramide, 10g glycerol, 1g glycyrrhizic glycoside are together added in aforementioned substrate, stirs according to same direction, be cooled to room temperature and get final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510006320.2A CN104546880B (en) | 2015-01-07 | 2015-01-07 | A kind of external preparation for treating facial seborrhea |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510006320.2A CN104546880B (en) | 2015-01-07 | 2015-01-07 | A kind of external preparation for treating facial seborrhea |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104546880A true CN104546880A (en) | 2015-04-29 |
| CN104546880B CN104546880B (en) | 2017-12-12 |
Family
ID=53064655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510006320.2A Active CN104546880B (en) | 2015-01-07 | 2015-01-07 | A kind of external preparation for treating facial seborrhea |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104546880B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017129643A1 (en) * | 2016-01-26 | 2017-08-03 | Nestec S.A. | Composition for preventing or reducing transepidermal water loss |
| CN107157993A (en) * | 2017-04-28 | 2017-09-15 | 广西信业生物技术有限公司 | It is a kind of to treat pharmaceutical composition of dry skin and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101732335A (en) * | 2009-12-08 | 2010-06-16 | 辽宁中医药大学 | Ointment medicament for treating acne and production method thereof |
| CN103860483A (en) * | 2012-12-13 | 2014-06-18 | 北京京卫信康医药科技发展有限公司 | Compound glycyrrhizin lyophilized powder injection and preparation method thereof |
-
2015
- 2015-01-07 CN CN201510006320.2A patent/CN104546880B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101732335A (en) * | 2009-12-08 | 2010-06-16 | 辽宁中医药大学 | Ointment medicament for treating acne and production method thereof |
| CN103860483A (en) * | 2012-12-13 | 2014-06-18 | 北京京卫信康医药科技发展有限公司 | Compound glycyrrhizin lyophilized powder injection and preparation method thereof |
Non-Patent Citations (4)
| Title |
|---|
| KARISHMA BYE BABAJEE: "《含马齿苋及牛油果树提取物的保湿霜治疗脂溢性皮炎的临床研究》", 25 February 2014 * |
| 孙萌: "《糠秕马拉色茵对表皮葡萄球菌和金黄色葡萄球菌增殖的影响》", 31 October 2014 * |
| 施仲香等: "脂溢性皮炎研究进展", 《中国麻风皮肤病杂志》 * |
| 董力新等: "临床常用消毒剂对烧伤创面细菌抑菌作用的比较研究", 《海南医学》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017129643A1 (en) * | 2016-01-26 | 2017-08-03 | Nestec S.A. | Composition for preventing or reducing transepidermal water loss |
| CN108472274A (en) * | 2016-01-26 | 2018-08-31 | 雀巢产品技术援助有限公司 | Composition for preventing or reducing percutaneous water loss |
| US10751308B2 (en) | 2016-01-26 | 2020-08-25 | Societe Des Produits Nestle S.A. | Composition for preventing or reducing transepidermal water loss |
| CN107157993A (en) * | 2017-04-28 | 2017-09-15 | 广西信业生物技术有限公司 | It is a kind of to treat pharmaceutical composition of dry skin and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104546880B (en) | 2017-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4418976B2 (en) | Antiseptic disinfectant and cosmetic composition | |
| ES2744425T3 (en) | Solution for acne | |
| JPS63500171A (en) | Pharmaceutical vehicles for reducing transdermal flow | |
| KR102587297B1 (en) | A composition for preventing or treating sleep disturbance | |
| US10226503B2 (en) | Plant extract composition for reducing topical fat and promoting weight loss as well as applications thereof | |
| AU2013359392C1 (en) | Compositions and methods for tissue regeneration | |
| CN105582383A (en) | Composition containing alkannin and lemon grass essential oil | |
| CN103347507A (en) | Melatonin and an antimicrobial or antibacterial agent for the treatment of acne | |
| CN101474284B (en) | External use medicament for treating fungal dermatopathy | |
| US20120225143A1 (en) | Cold sore formulation and related method of manufacture | |
| CN107519236A (en) | A kind of topical agent for treating onychomycosis | |
| JP6753312B2 (en) | Topical skin preparation for medical use | |
| CN104546880A (en) | External preparation for treating facial seborrheic dermatitis | |
| US8529966B2 (en) | Burn treatment composition and method | |
| US20200384051A1 (en) | Herbal formulations of carnivorous plants and methods for treating inflammation | |
| ES2880437T3 (en) | New topical compositions comprising usnic acid and its therapeutic use | |
| CN110123860B (en) | Preparation method of lithospermum silicone oil and composition preparation thereof | |
| US20200085902A1 (en) | Composition and method for treating itching, burning and discomfort of the skin | |
| US11344505B1 (en) | Herbal formulations of carnivorous plants and methods for treating inflammation | |
| ITUB20159582A1 (en) | Composition, for topical use, useful for the prevention of inflammatory and / or infectious mucosal disorders. | |
| US7863277B1 (en) | Topical antipsychotic composition | |
| WO2019241409A1 (en) | Topical composition for pain relief | |
| CN104490870A (en) | Compound topical cream and application thereof | |
| CN103585330B (en) | A kind of Chinese medicine composition for cutaneous fungal infection and preparation method thereof | |
| CN104306436B (en) | A kind of Quick itch stopping sterilized articles therefrom |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: An Qian Inventor after: Gao Xinghua Inventor after: Chen Hongduo Inventor after: Qi Ruiqun Inventor after: Zhang Li Inventor after: Lan Jing Inventor before: An Qian Inventor before: Gao Xinghua Inventor before: An Qian, Gao Xinghua, Chen Hongduo |
|
| COR | Change of bibliographic data | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20190627 Address after: 116000 Dalian Economic and Technological Development Zone, Liaoning Province, No. 80, Shengli Road, ShuangD Port Patentee after: Dalian Asia Pharmaceutical Co. Ltd. Address before: 110001 No. 155 Nanjing North Street, Heping District, Shenyang City, Liaoning Province Patentee before: Attached Hospital No.1 China Univ. of Medical Science |
|
| TR01 | Transfer of patent right |